search
Back to results

Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer (BRASTEGAC)

Primary Purpose

Adenocarcinoma of the Esophago-gastric Junction

Status
Unknown status
Phase
Phase 2
Locations
Poland
Study Type
Interventional
Intervention
Brachytherapy
Endoscopic stenting
Sponsored by
Medical University of Lublin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adenocarcinoma of the Esophago-gastric Junction focused on measuring adenocarcinoma, esophago-gastric junction, dysphagia, brachytherapy, endoscopic stenting

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adenocarcinoma of the esophago-gastric junction defined as adenocarcinoma involving lower esophagus and upper stomach with epicenter of the primary tumor between 5cm above and 5cm below the anatomic esophago-gastric junction
  • Inoperable cancer - locally advanced irresectible cancer, distant metastasis or patient's condition does not fit to undergo a curative therapy
  • Dysphagia score 2-4
  • Performance status 60-100
  • Signed informed consent

Exclusion Criteria:

  • Esophageal squamous cell carcinoma
  • Esophageal adenocarcinoma
  • Gastric cancer
  • Performance status <60
  • Instable cardiocirculatory or respiratory disorder
  • Concurrent external beam radiation therapy
  • Previous anticancer therapy related to current adenocarcinoma of the esophago-gastric junction

Sites / Locations

  • Second Department of General & Gastrointestinal Surgery & Oncological Surgery of the Alimantary Tract, Medical University of LublinRecruiting
  • St. John's Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Brachytherapy

Endoscopic Stenting

Arm Description

Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.

Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively

Outcomes

Primary Outcome Measures

The highest improvement of dysphagia grade
Time to the best swallowing improvement
Time to recurrent worsening of swallowing
The highest improvement of stricture diameter

Secondary Outcome Measures

the procedure related morbidity
the procedure related mortality
The frequency of dysphagia related additional endoscopic interventions
Overall survival
Quality of life

Full Information

First Posted
February 5, 2013
Last Updated
February 5, 2013
Sponsor
Medical University of Lublin
Collaborators
St Johns' Oncology Center in Lublin
search

1. Study Identification

Unique Protocol Identification Number
NCT01786278
Brief Title
Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer
Acronym
BRASTEGAC
Official Title
The Comparison of Value of Brachytherapy and Endoscopic Stenting With SEMS in Palliative Treatment of Dysphagia Resulting From Adenocarcinoma of the Esophago-Gastric Junction
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Unknown status
Study Start Date
February 2013 (undefined)
Primary Completion Date
February 2016 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Lublin
Collaborators
St Johns' Oncology Center in Lublin

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the study is comparison of the efficacy and safety of palliative therapy with single-dose brachytherapy or selfexpanding metal stents (SEMS) in malignant dysphagia resulting from adenocarcinoma of the esophago-gastric junction.
Detailed Description
Over the past two decades it has been observed a clear trend in the increasing incidence of adenocarcinoma of the esophagus and esophago-gastric junction. More than half of these patients already have inoperable disease at presentation. Most of them need palliative treatment to relieve progressive dysphagia. Presently, endoscopic placement of a covered selfexpanding metal stent is the most commonly used method for treatment of malignant dysphagia. Cancer overgrowth and stent migration are the most common complications of endoscopic stenting and they occur more frequently with longer time from stenting. Specific location at esophago-gastric junction at the end point of the propulsive force after swallow may predispose stents for easier migration to the stomach. Additionally, the advances in chemotherapy have resulted in improved median survival of advanced adenocarcinoma ot the stomach and esophago-gastric junction even up to 10-12 months increasing a potential for higher chance for occurrence of stent complications. Brachytherapy has been proved to be a valuable and durable method to treat malignant dysphagia resulting from esophageal and mainly squamous cell cancer. For many years irradiation was not recommended for adenocarcinoma of the esophagus and esophago-gastric junction due to their putative low sensitivity to radiotherapy. Recently external beam radiation has been incorporated to a combined modality therapy regimens also for adenocarcinoma of the esophagus. Thus, brachytherapy could be an attractive and durable method for improving swallowing in adenocarcinoma of the esophago-gastric junction, as well. Single-dose brachytherapy and endoscopic stenting with SEMS in relieving dysphagia resulting from clearly defined adenocarcinoma of the esophago-gastric junction have not been compared yet.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenocarcinoma of the Esophago-gastric Junction
Keywords
adenocarcinoma, esophago-gastric junction, dysphagia, brachytherapy, endoscopic stenting

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Brachytherapy
Arm Type
Experimental
Arm Description
Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
Arm Title
Endoscopic Stenting
Arm Type
Other
Arm Description
Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
Intervention Type
Radiation
Intervention Name(s)
Brachytherapy
Intervention Description
Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
Intervention Type
Procedure
Intervention Name(s)
Endoscopic stenting
Intervention Description
Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
Primary Outcome Measure Information:
Title
The highest improvement of dysphagia grade
Time Frame
1 year
Title
Time to the best swallowing improvement
Time Frame
1 year
Title
Time to recurrent worsening of swallowing
Time Frame
1 year
Title
The highest improvement of stricture diameter
Time Frame
1 year
Secondary Outcome Measure Information:
Title
the procedure related morbidity
Time Frame
1 year
Title
the procedure related mortality
Time Frame
1 year
Title
The frequency of dysphagia related additional endoscopic interventions
Time Frame
1 year
Title
Overall survival
Time Frame
1 year
Title
Quality of life
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Cost analysis
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adenocarcinoma of the esophago-gastric junction defined as adenocarcinoma involving lower esophagus and upper stomach with epicenter of the primary tumor between 5cm above and 5cm below the anatomic esophago-gastric junction Inoperable cancer - locally advanced irresectible cancer, distant metastasis or patient's condition does not fit to undergo a curative therapy Dysphagia score 2-4 Performance status 60-100 Signed informed consent Exclusion Criteria: Esophageal squamous cell carcinoma Esophageal adenocarcinoma Gastric cancer Performance status <60 Instable cardiocirculatory or respiratory disorder Concurrent external beam radiation therapy Previous anticancer therapy related to current adenocarcinoma of the esophago-gastric junction
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tomasz Skoczylas, MD, PhD
Phone
+48 81 5328810
Email
tomskocz@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tomasz Skoczylas, MD, PhD
Organizational Affiliation
Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Krzysztof Zinkiewicz, MD, PhD
Organizational Affiliation
Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Grzegorz Wallner, Professor
Organizational Affiliation
Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elżbieta Starosławska, MD, PhD
Organizational Affiliation
St Johns' Oncology Center in Lublin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dariusz Kieszko, MD, PhD
Organizational Affiliation
St Johns' Oncology Center in Lublin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Second Department of General & Gastrointestinal Surgery & Oncological Surgery of the Alimantary Tract, Medical University of Lublin
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-081
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomasz Skoczylas, MD, PhD
Phone
+48 81 5328810
Email
tomskocz@yahoo.com
First Name & Middle Initial & Last Name & Degree
Tomasz Skoczylas, MD, PhD
First Name & Middle Initial & Last Name & Degree
Krzysztof Zinkiewicz, MD, PhD
First Name & Middle Initial & Last Name & Degree
Witold Zgodziński, MD, PhD
First Name & Middle Initial & Last Name & Degree
Marek Majewski, MD, PhD
First Name & Middle Initial & Last Name & Degree
Grzegorz Wallner, Professor
First Name & Middle Initial & Last Name & Degree
Andrzej Dąbrowski, Professor
First Name & Middle Initial & Last Name & Degree
Witold Krupski, Professor
Facility Name
St. John's Cancer Center
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-090
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dariusz Kieszko, MD, PhD
Phone
+48 81 7477511
Ext
142
First Name & Middle Initial & Last Name & Degree
Elżbieta Starosławska, MD, PhD
First Name & Middle Initial & Last Name & Degree
Dariusz Kieszko, MD, PhD
First Name & Middle Initial & Last Name & Degree
Paweł Cisek, MD
First Name & Middle Initial & Last Name & Degree
Krzysztof Paprota, MD, PhD
First Name & Middle Initial & Last Name & Degree
Tomasz Kubiatowski, MD, PhD
First Name & Middle Initial & Last Name & Degree
Bożena Kukiełka-Budny, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer

We'll reach out to this number within 24 hrs